Désiré Collen

Désiré Collen

Désiré Collen blends fundamental and translational research with business enterprise.
Born Désiré Collen
(1943-06-21)21 June 1943
Sint-Truiden, Belgium
Residence London, UK
Citizenship Belgian
Nationality Belgium
Fields
Spouse Louisa Reniers (m. 1966)
Children
  • An Collen
  • Peter Collen
  • Christine Collen

Désiré, Baron Collen (born in Sint-Truiden, Belgium, 21 June 1943) is a Belgian physician, chemist, biotechnology entrepreneur and life science investor.[1] He made several discoveries in thrombosis, haemostasis and vascular biology in many of which serendipity played a significant role.[2] His main achievement has been his role in the development of tissue-type plasminogen activator (t-PA) from a laboratory concept to a life-saving drug for dissolving blood clots causing acute myocardial infarction or acute ischemic stroke. Recombinant t-PA was produced and marketed by Genentech Inc as Activase and by Boehringer Ingelheim GmbH as Actilyse, and is considered biotechnology’s first life saving drug.[3]

In 2008 Collen reached the mandatory retirement age of 65 years as Professor of the Faculty of Medicine at KU Leuven (Belgium), where he served as Director of the Center for Thrombosis and Vascular Research (now Center for Molecular and Vascular Biology) and the VIB Department for Transgene Technology and Gene Therapy (now VIB-KU Leuven Center for Cancer Biology). He authored and co-authored over 650 research papers in peer reviewed international journals which as of mid 2017 have been cited over 70,000 times. He was ranked among the 100 most cited scientific authors of the 1980s [4] and among the top 100 living contributors to biotechnology in polls conducted by Reed Elsevier in 2005.[5] In 2012 SciTech Strategies placed him among the top 400 most influential scientists in biomedical research for the period 1996-2011.[6]

In 1988, Désiré Collen founded the ‘D. Collen Research Foundation vzw’,[7][8] a not-for-profit organization with the mission to invest the mayor part of the royalties earned from Genentech on the t-PA patent in scientific research. The Foundation was renamed in 2007 into ‘Life Sciences Research Partners vzw’ [9] of which Collen remains the Statutory Chairman.[10]

In 1991 he spun out the company Thromb-X nv from the KU Leuven in Belgium. The primary focus of Thromb-X was in the cardiovascular space with an initial effort to develop staphylokinase as a more affordable thrombolytic medicine compared to t-PA (“poor man’s t-PA"). With the constitution of ThromboGenics Ltd in Ireland in 1998, the company expanded its R&D scope to include cardiovascular, oncology and ophthalmology programs.[11] ThromboGenics developed ocriplasmin, a truncated form of plasmin, for the treatment of vitreomacular traction in the eye.[12][13] Disappointed by the, in his opinion inadequate strategic and commercial governance of the company, Collen left ThromboGenics as Chairman and board member in December 2013.[14]

With the help of Chris Buyse , his CFO and “companion de route” during their 7 years at ThromboGenics, he co-financed the start of Fund+, an ever-green investment fund that currently manages over 139 million euro . Fund+ is a private Fund for long term equity investment in innovative life sciences companies with a strong patient-centered approach aiming at both a financial return and a tangible societal impact.[15]

King Albert II of Belgium awarded Désiré Collen hereditary nobility, with the personal rank of Baron in 2012. He was also recipient of the Belgian Francqui Prize, Louis-Jeantet Prize for Medicine, Bristol-Myers Squibb Award for Cardiovascular Research, Interbrew-Baillet Latour Health Prize, Insead Innovator Prize, Robert P. Grant Medal of the International Society for Thrombosis and Haemostasis , Lifetime Achievement Award of the Belgian-American Chamber of Commerce (BelCham) , and Lifetime Achievement Award of Scrip. He received honorary doctorates from Erasmus University, Rotterdam, the Netherlands; Free University of Brussels (VUB), Brussels, Belgium; University of Notre Dame, Notre Dame, IN, United States; and Université de la Méditerranée, Marseille, France.[1]

Education

Désiré Collen, born on 21 June 1943 in the Flemish town of Sint-Truiden as the first of two children of Frans Collen and Maria Hoebrechs, started his studies in medicine at the University of Leuven (KU Leuven) in 1961. Since his third year of the seven year curriculum he combined his studies with research: first in the laboratory of Belgian physiologist Professor Joseph P. Bouckaert, and from the next year on in the Laboratory for Blood Coagulation under the direction of Professor Marc Verstraete . Under the guidance of young gastroenterologist Guido Tytgat and biochemist René De Vreker he studied the rate at which the coagulation proteins fibrinogen and plasminogen are cleared from the circulation. This early experience with biochemical lab work inspired Désiré Collen to become a researcher rather than a practicing general physician or medical specialist. Realising his knowledge in chemistry was inadequate, he combined his education in medicine with academic studies in chemistry. He graduated from the KU Leuven as Doctor in Medicine in 1968 and as Master (“Licentiaat”) in Chemistry in 1969.[1]

Mid 1968 Désiré Collen became research assistant of the Belgian National Fund for Scientific Research in the Laboratory of Marc Verstraete. He worked simultaneously in the Department of Physical Chemistry under the supervision of Professor Leo De Maeyer . He started a research project on factors influencing the polymerization of fibrinogen to fibrin.[1] Only months later, he published his first, although a very short one, scientific paper in Nature.[16]

In 1971-1972 he went as an Associate Research Scientist of the National Institutes of Health (United States) to the New York University Medical Center to work with Alan Johnson. In 1972-1973 he worked in the laboratory of Birger Blombäck[17] at Karolinska Institutet in Stockholm (Sweden) as a NATO Research Fellow. After obtaining his Ph.D. in Chemistry at the KU Leuven in 1974 and concluding his mandatory military service, Désiré Collen was appointed in 1976 as Lecturer (Docent) in the Faculty of Medicine at KU Leuven and as Adjunct Head of Clinic in the Section Bleeding and Vascular Diseases in the Department of Internal Medicine at the University Hospital Leuven.[1]

Career and research

Research output

The scientific output of Désiré Collen between 1968 and 2008 consists of over 650 peer-reviewed research papers in international journals, 170 review articles and 28 issued US patents. His publications have been cited over 70,000 times in the scientific literature.[1] He made seminal contributions to the fields of thrombosis, haemostasis and vascular biology.[2] His pivotal achievement has been the development of tissue-type plasminogen activator (t-PA) from a laboratory concept to the first life saving biotech drug. Recombinant t-PA has been primarily used for dissolving blood clots causing acute myocardial infarction or acute ischemic stroke.[3]

The cloning of t-PA and preclinical research

T-PA is a protease that converts inactive plasminogen into active plasmin, which in turn cleaves fibrin, the main component of blood clots. Upon cleavage of the long fibrin strands by plasmin, the clot falls apart and dissolves. Between August 1977 and September 1978 Désiré Collen and Bjorn Wiman elucidated that the conversion of plasminogen to plasmin takes place when both proteins are bound to fibrin in the blood clot.[18][19][20] This molecular model for the regulation and control of fibrinolysis was presented in 1979 during an invited plenary lecture (Edward Kowalski Memorial Lecture) at the VIIth International Congress on Thrombosis and Haemostasis in London. The written report of this presentation has been cited over 1000 times in the scientific literature.[21]

Collen collaborated in the same period with Professor Alfons Billiau of the Rega Institute for Medical Research in Leuven, Belgium on the inhibition of plasminogen activators secreted by malignant cells in culture, hypothesizing that synthetic inhibitors might suppress the malignant phenotype of these cells. In order to have a source for these “malignant plasminogen activators” the Bowes Melanoma Cell line was obtained from Professor Daniel Rifkin of the Rockefeller University, New York City at the end of 1978. It quickly appeared that this cell line produced large amounts of a plasminogen activator with a molecular weight of 70,000 dalton and a high affinity for fibrin, characteristic of human tissue-type plasminogen activator (t-PA), whereas most other malignant cells produced a plasminogen activator with a molecular weight of 54,000 dalton without affinity for fibrin, which is characteristic of pro-urokinase. This game-changing, although trivial serendipitous observation, made on 9 February 1979,[1] was to change the course of thrombolytic therapy.

In order to produce sufficient amounts of t-PA for further biochemical and preclinical studies, post-doctoral fellow Dingeman (Dick) Rijken succeeded in isolating sufficient amounts of pure and homogeneous t-PA from conditioned culture medium from the Bowes Melanoma Cell line.[22][23] This purified protein was used by post-doctoral fellow Osamu Matsuo to evaluate the thrombolytic potential of t-PA in rabbits suffering from an experimental pulmonary embolus.[24] The research led to a key patent (US4752603) entitled ‘Plasminogen activator and pharmaceutical composition having thrombolytic activity’ [25] which was first submitted in the Netherlands on 11 June 1980.

On 12 June 1980, one day after the submission of the patent application, Collen presented the results at the Fifth Congress on Fibrinolysis in Malmö (Sweden) in the presence of Diane Pennica , a young scientist from biotech company Genentech Inc, based in South San Francisco. Collen, KU Leuven and Genentech agreed to collaborate on the production of a recombinant version of t-PA (rt-PA), embarking on a new model for drug development: academic and biotech collaboration, today routine, but at that time a new modus operandi.[1] Within 18 months, Pennica and her team had cloned the cDNA (complementary DNA) of human t-PA messenger RNA and was producing rt-PA in cultures of Chinese hamster ovary cells.[26]

The therapeutic potential of rt-PA and its functional identity with natural t-PA was proven in a collaboration with Steven R. Bergman and Burton Sobel (Washington University School of Medicine, Saint Louis), Frans Van de Werf (KU Leuven), and Herman 'Chip' Gold and Tsunehori Yasuda (Massachusetts General Hospital, Harvard Medical School, Boston) using canine models of coronary thrombosis.[27][28][29]

Clinical studies with t-PA

Also in 1981, following a discussion with Alfons Billiau at a scientific congress in Amsterdam, Dutch nephrologist Willem Weimar of the Dijkzigt Hospital in Rotterdam treated for the first time a patient with t-PA purified from the Bowes Melanoma Cell line. The patient, a 29 year old lady, was suffering from a renal transplant vein thrombosis and was successfully treated resulting in a decennia-long survival.[30] Cardiologists Frans Van de Werf and Burton Sobel tested t-PA in 1983 in a pilot clinical study on patients with acute myocardial infarction.[31] Also in 1983, the first prospective, randomized and placebo-controlled trial of recombinant t-PA took place in three US hospitals.[32]

The subsequent NIH Thrombolysis in Acute Myocardial Infarction (TIMI) trials led by Eugene Braunwald (Brigham and Women’s Hospital, Harvard School of Medicine, Boston),[33][34][35][36] and the European Cooperative Study Group Trials led by Marc Verstraete (KU Leuven)[37][38] culminated in the final approval of rt-PA as thrombolytic agent by the FDA on 13 November 1987.[39] Genentech immediately started to market the drug in the US under the brand name Activase®,[40] while Boehringer Ingelheim would distribute the drug in the rest of the world (except Japan) as Actilyse®.

A lifesaving drug

The controversy over whether the more expensive rt-PA was clinically superior over streptokinase as a thrombolytic agent climaxed in the scientific press between 1988 and 1992.[41][42][43][44] To end this controversy, the GUSTO trial (Global Utilization of Streptokinase and t-PA for Occluded Coronary Arteries) was set up, a head-to-head comparison between rt-PA and streptokinase. In the GUSTO-trial 41,021 heart attack patients were treated in 1,081 hospitals in 15 countries. Cardiologist Eric Topol of the Cleveland Clinic (USA), statistician Robert Califf of Johns Hopkins (USA) and David Stump of Genentech coordinated the trial. In absolute figures the 30-day mortality rate in the rt-PA group was 1% lower (or in relative figures 14%) compared to the mortality in the streptokinase group.[45][46][47] After the GUSTO studies, rt-PA became the thrombolytic drug of choice for most of the cardiologists in the Western world and would save the lives of many tens of thousands of heart attack patients.[3]

Nowadays, cardiologists agree that timely performed percutaneous coronary intervention (PCI), also known as 'angioplasty’ and ‘stenting', is the preferred strategy to treat acute myocardial infarction instead of thrombolysis. PCI is associated with less mortality on the short term (7% versus 9% for thrombolysis), a lower risk of a recurrent infarct (3% versus 7%) and a lower frequency of cerebral hemorrhage (1% versus 2%). Also over a longer period of time, PCI leads to a lower mortality rate.[48]

However, because access to invasive facilities is limited in many countries, thrombolytic therapy is still employed in many centers worldwide for treating acute myocardial infarction.[49] Moreover, r[50] based [51] still is an important strategy to treat ischemic stroke [52][53] and to a lesser extent, pulmonary embolism[54][55] and deep vein thrombosis;[56] it has even been used to restore the blood flow in occluded central venous access ports and in the frozen limbs of mountaineers, resulting in a spectacular decrease in the amputation rate.[57]

Staphylokinase - poor man's t-PA

On many occasions Désiré Collen expressed his frustration that the lives of many more people could have been saved, had rt-PA been more readily available, also to people who were not living in the affluent western world.[1] Therefore, he invested part of Genentech’s t-PA royalty stream in the search for a “t-PA for the poor”.

In the early 1990s, together with Roger Lijnen (KU Leuven) and Osamu Matsuo (Kindai University, Osaka, Japan), Collen started to evaluate whether staphylokinase (STAR), a bacterial profibrinolytic agent with high fibrin specificity, could be a valid alternative for rt-PA in less wealthy territories.[58] By setting up spin off company Thromb-X, Collen had the clear objective to further develop staphylokinase through the preclinical and clinical research phases up to the market introduction. Although wild type staphylokinase and variants with reduced immunogenicity and preserved lytic potency have been tested with success in humans,[59][60] its further development came to an unfortunate standstill because of the prohibitive expense of a GUSTO-like clinical trial with a mortality end-point that had become the standard in the West. Not even licensing out the further clinical development, production and commercialization of staphylokinase to companies in developing countries (where for most people rt-PA is hardly available) could save this project.[61][62][63]

VIB Department for Transgene Technology and Gene Therapy

With the constitution of the Flemish Institute for Biotechnology (Vlaams Instituut voor Biotechnologie - VIB), Collen was able to extend the capacity of his Leuven based academic research laboratories. He became Director of the VIB Department for Transgene Technology and Gene Therapy (now VIB-KU Leuven Center for Cancer Biology) based on the Gasthuisberg Campus of the KU Leuven. Together with Professor Peter Carmeliet and colleagues, landmark contributions were made to the fields of vascular biology, tumor biology and neurobiology, e.g. between 1995 and 2008 the Department conducted breakthrough research on the role of vascular endothelial growth factor (VEGF) and placental growth factor (PlGF) in angiogenesis,[64][65][66] cancer[67][68] and amyotrophic lateral sclerosis (ALS).[69][69]

Academic Appointments

From 1981 to 2008 Désiré Collen was Professor at the Faculty of Medicine of the KU Leuven in Belgium. Between 1998 and 2002 he temporarily resigned to develop ThromboGenics, but remained ‘Extraordinary Professor’ (Buitengewoon hoogleraar). In 2008 he reached the age of mandatory retirement at Belgian Universities.[1]

Désiré Collen was also Professor of Biochemistry and Medicine in the Department of Kenneth G. Mann at the University of Vermont College of Medicine, Burlington, Vermont, USA (1984-2005), Visiting Professor of Medicine in the group of Herman 'Chip' Gold of Massachusetts General Hospital at Harvard School of Medicine, Boston, MA, USA (1987-1994), Consultant in Medicine at the Massachusetts General Hospital, Boston, MA, USA (1987-2005) and Visiting Professor at the Division of Surgery and Anaesthesia of Kevin Burnand at United Medical and Dental Schools of Guy's and St Thomas' Hospitals, London, UK (1999-2002).[1]

Désiré Collen was Director of the Center for Molecular and Vascular Biology at the Faculty of Medicine of the KU Leuven from 1994 to 2008, Division Head of the Protein Research Division of Leuven Research and Development vzw of the KU Leuven from 1976 to 1998 and Director of the Department for Transgene Technology and Gene Therapy of the Vlaams Instituut voor Biotechnologie (VIB) from 1994 to 2008.[1]

D. Collen Research Foundation

On 2 July 1988 the D. Collen Research Foundation was constituted by Désiré Collen, Roger Dillemans , Rector of the KU Leuven, Karel Tavernier, General Manager of the KU Leuven, Jacques Vander Eecken, Chairman of Leuven Research and Development and Lawrence Fouraker, former Dean of the Harvard Business School representing the Harvard Medical School.[1] The mission of the Foundation was to canalize the major part of the income from the rt-PA royalties towards “the execution, promotion and support of scientific research in general, and biomedical and biotechnological research in particular, by making available research grants, research positions, travel bursaries, by organizing scientific congresses and symposia, providing financial support for publications and all related activities that support the advancement of science.” With the support of the Foundation, over 100 young researchers were able to obtain further specialisation abroad; numerous congresses and symposia and two academic chairs were sponsored, the 9th floor of the research building on the Gasthuisberg Research Campus and a guesthouse on the Groot Begijnhof campus were built with financial support of the Foundation. These buildings housed for many years the Center for Thrombosis and Vascular Research and the VIB Department for Transgene Technology and Gene Therapy and their postdoctoral researchers, respectively.[1]

In 2007 the D. Collen Research Foundation was renamed to Life Sciences Research Partners vzw . It continued the activities of the D. Collen Research Foundation, but also started to invest in life science companies, such as Celyad , Ogeda , Amakem, Bone Therapeutics and others.[70]

Thromb-X and ThromboGenics

In 1991, Désiré Collen spun out Thromb-X nv from the KU Leuven with an initial mission to develop staphylokinase as an equally effective but less expensive successor of rt-PA. With the foundation of ThromboGenics Ltd in Ireland in 1998, the Company expanded its R&D scope to include various cardiovascular, oncology and ophthalmology programs in-licensed from the KU Leuven and the Vlaams Instituut voor Biotechnologie (Flemish Institute for Biotechnologie - VIB). Collen was CEO and Chairman of ThromboGenics from 1998 to 2008. In 2008 Patrick De Haes succeeded him as CEO.

Following a successful IPO in 2006 on the basis of the expanded R&D portfolio, the company nevertheless narrowed its scope to the clinical development of ocriplasmin, a truncated form of plasmin for ophthalmology indications, culminating in the completion of a pivotal phase III program in 2010.[71][72] Following FDA approval, ThromboGenics launched ocriplasmin, marketed as Jetrea®, in the US on 14 January 2013 for the treatment of symptomatic vitreomacular adhesion (VMA).[73] Three months later, the European Commission approved ocriplasmin,[74] a decision that paved the way for Alcon to launch the product under licence of ThromboGenics. Disappointed by the, in his opinion, inadequate strategic and commercial governance of the company, Collen stepped down as Chairman and member of the board in December 2013.[14]

Fund+

In May 2015 Désiré Collen, through the private foundation Désiré Collen Stichting and the non-profit organisation Life Sciences Research Partners, founded Fund+ of which he is the Chairman. Fund+ will invest in innovative life sciences companies seeking series A or B financing and with a Proof of Concept in therapeutics, diagnostics or medical devices. The Fund made investments in Ogeda (acquired by Astellas), Iteos , MaSTherCell , Promethera , Q-Biologicals (acquired by Amatsi Group ), Novadip , eTheRNA and Octimet . Fund+ aims at realizing an attractive financial return for its investors, as well as a societal return. Fund+ wants to contribute in a sustainable way to the improvement of the eco system for biotech companies. Therefore, its major geographical focus will be Belgium. As of July 2017 Fund+ had raised over 139 Million euro of financing commitments. The intended investment size per company will be between 3 and 10 million euro spread over different milestones.

Awards and honours

Désiré Collen was awarded the Belgian Francqui Prize in Biological and Medical Sciences in 1984. He received the Louis-Jeantet Prize for Medicine (Fondation L. Jeantet, Geneva, Switzerland) in 1986, the Bristol-Myers Squibb Award for Cardiovascular Research (New York, NY, USA) jointly with Mark Verstraete in 1994, the Interbrew-Baillet Latour Health Prize (Belgium) jointly with Peter Carmeliet in 2005, the Harvard Leadership Prize by the Harvard Club of Belgium in 2007, the Insead Innovator Prize in 2009, the Robert P. Grant Medal from the International Society for Thrombosis and Haemostasis in 2011, the Lifetime Achievement Award of Belcham (New York, NY, USA) in 2013 and the Lifetime Achievement Award of Scrip (London, UK) in2013

He became Ereburger (Honorary Citizen) of his native town Sint-Truiden (Belgium) in 2013 and Alumnus of the Year 2014 of Alfagen KU Leuven. In 2012 his majesty King Albert II of Belgium awarded him the hereditary nobility status (personal title of Baron).

In addition he received honorary doctorates from Erasmus University, Rotterdam (The Netherlands) in 1988, Free University of Brussels (VUB), Brussels (Belgium) in 1994, University of Notre Dame, Notre Dame (IN, USA) in 1995 and Université de la Méditerranée, Marseille (France) in 1999.

Books

Collen’s memoires (in Dutch) ‘Een hart voor onderzoek en ondernemen’ were published in 2009 by VandenBroele (ISBN 9789049600563).

References

  1. 1 2 3 4 5 6 7 8 9 10 11 12 13 14 Memoires Désiré Collen (2009) Een hart voor onderzoek en ondernemen. ISBN 978 90 4960 056 3
  2. 1 2 Lijnen R. Retirement of Désiré Collen. J Thromb Haemost. 2009 Jan;7(1):2-3. doi:10.1111/j.1538-7836.2008.03194.x. Epub 2008 Oct 18. PMID 18983506.
  3. 1 2 3 Delude C. Clot-Busters !! – Discovery of thrombolitic therapy for treating heart attack and stroke. Breakthroughs in Bioscience, FASEB 2004, 6.
  4. ↑ Current contents, 31 Aug 1992, p.3
  5. ↑ The top 100 Living Contributors to Biotechnology, http://www.goldenrice.org/PDFs/Top_100.pdf
  6. ↑ Boyack KW, Klavans R, Sorensen AA, Ioannidis JP. A list of highly influential biomedical researchers, 1996-2011. Eur J Clin Invest. 2013 Dec;43(12):1339-65 doi:10.1111/eci.12171. Epub 2013 Oct 21. PMID 24134636.
  7. ↑ Collen Foundation opgericht. Financieel Economische Tijd. 8 November 1988, http://www.lsrp.be/pdfs/tijd_1988_11_08.png
  8. ↑ Oprichting D. Collen Research Foundation aan KULeuven – Fondsen t-PA stimuleren biomedisch onderzoek. De Standaard, 8 November 1988, http://www.lsrp.be/pdfs/Standaard1_1988_11_08.png
  9. ↑ http://www.lsrp.be
  10. ↑ Life Sciences Research Partners vzw, Current Contents August 31, 1982, p3. http://www.lsrp.be/index.html
  11. ↑ Our history. ThromboGenics. http://www.thrombogenics.com/about-us/our-history
  12. ↑ FDA Approves Ocriplasmin for Vitreomacular Adhesions. Medscape Medical News. 18 October 2012. http://www.medscape.com/viewarticle/772845
  13. ↑ Prospero Ponce CM, Stevenson W, Gelman R, Agarwal DR, Christoforidis JB. Ocriplasmin: who is the best candidate? Clin Ophthalmol. 2016 Mar 17;10:485-95. doi:10.2147/OPTH.S97947. eCollection 2016. Review. PMID 27051270; PMC 4803238.
  14. 1 2 ThromboGenics’ Founder Prof Désiré Collen Retiring as Chairman. ThromboGenics Press Release. 6 December 2013. http://www.thrombogenics.com/sites/default/files/upload/news/THR_13_30DesireChairmanfinal.pdf
  15. ↑ Fund+ Impacting Life Sciences. http://fundplus.be
  16. ↑ Collen D, Vandereycken G, De Maeyer L. Influence of hydrostatic pressure on the reversible polymerization of fibrin monomers. Nature. 1970 Nov 14;228(5272):669-71. PMID 5529056.
  17. ↑ Lord ST, Henschen-Edman A. Birger Blombäck (May 7, 1926 - October 2, 2008). J Thromb Haemost. 2009 May;7(5):908-9. doi:10.1111/j.1538-7836.2009.03320.x. Epub 2009 Feb 13. PMID 19220733; PMC 2965830.
  18. ↑ Wiman B, Collen D. Molecular mechanism of physiological fibrinolysis. Nature. 1978; 272: 549-50.
  19. ↑ Collen D, Wiman B. Fast-acting plasmin inhibitor in human plasma. Blood. 1978; 51: 563-9. Review.
  20. ↑ Collen D, Wiman B. The fast-acting plasmin inhibitor of human plasma: The Prix Servier Lecture 1978. In: ‘Progress in Chemical Fibrinolysis and Thrombolysis, Vol. 4’. Ed.: J.F. Davidson. Churchill Livingstone, Edinburg, 1979; 11-19.
  21. ↑ Collen D. On the regulation and control of fibrinolysis. Edward Kowalski Memorial Lecture. Thromb Haemost. 1980; 43: 77-89. Review.
  22. ↑ Rijken DC and Collen D. Purification and characterization of the plasminogen activator secreted by human melanoma cells in culture. J Biol Chem. 1981; 256: 7035-41.
  23. ↑ Collen D, Rijken DC, Van Damme J, Billiau A. Purification of human tissue-type plasminogen activator in centigram quantities from human melanoma cell culture fluid and its conditioning for use in vivo. Thromb Haemost. 1982; 48: 294-6.
  24. ↑ Matsuo O, Rijken DC, Collen D. Thrombolysis by human tissue plasminogen activator and urokinase in rabbits with experimental pulmonary embolus. Nature. 1981; 291: 590-1.
  25. ↑ Collen DJ, Rijken DC, Matsuo OM. Plasminogen activator and pharmaceutical composition having thrombolytic activity. US 4752603. http://www.google.com/patents/US4752603
  26. ↑ Pennica D. et al. Cloning and expression of human tissue-type plasminogen activator cDNA in E. coli. Nature. 1983 Jan 20;301(5897):214-21.
  27. ↑ Bergmann SR, Fox KA, Ter-Pogossian MM, Sobel BE, Collen D. Clot-selective coronary thrombolysis with tissue-type plasminogen activator. Science. 1983; 220: 1181-3.
  28. ↑ Van de Werf F et al. Coronary thrombolysis with intravenously administered human tissue-type plasminogen activator produced by recombinant DNA technology. Circulation. 1984; 69: 605-10.
  29. ↑ Gold HK et al. Coronary thrombolysis with recombinant human tissue-type plasminogen activator. Circulation. 1984; 70: 700- 7.
  30. ↑ Weimar W, Stibbe J, van Seyen AJ, Billiau A, De Somer P, Collen D. Specific lysis of an iliofemoral thrombus by administration of extrinsic (tissue-type) plasminogen activator. Lancet. 1981; 2: 1018-20.
  31. ↑ Van de Werf F et al. Coronary thrombolysis with tissue-type plasminogen activator in patients with evolving myocardial infarction. N Engl J Med. 1984; 310: 609-13.
  32. ↑ Collen D et al. Coronary thrombolysis with recombinant human tissue-type plasminogen activator: a prospective, randomized, placebo-controlled trial. Circulation. 1984 Dec; 70: 1012-7.
  33. ↑ The Thrombolysis in Myocardial Infarction (TIMI) trial. Phase I findings. TIMI Study Group. N Engl J Med. 1985; 312: 932-6.
  34. ↑ Sheehan FH et al., The effect of intravenous thrombolytic therapy on left ventricular function: a report on tissue-type plasminogen activator and streptokinase from the Thrombolysis in Myocardial Infarction (TIMI Phase I) trial. Circulation. 1987; 75: 817-29.
  35. ↑ Chesebro JH et al. Thrombolysis in Myocardial Infarction (TIMI) Trial, Phase I: A comparison between intravenous tissue plasminogen activator and intravenous streptokinase. Clinical findings through hospital discharge. Circulation. 1987; 76: 142-54.
  36. ↑ Mueller HS, Rao AK, Forman SA. Thrombolysis in myocardial infarction (TIMI): comparative studies of coronary reperfusion and systemic fibrinogenolysis with two forms of recombinant tissue-type plasminogen activator. J Am Coll Cardiol. 1987; 10: 479-90.
  37. ↑ Verstraete M et al. Double-blind randomised trial of intravenous tissue-type plasminogen activator versus placebo in acute myocardial infarction. Lancet. 1985; 2: 965-9.
  38. ↑ Verstraete M et al. Randomised trial of intravenous recombinant tissue-type plasminogen activator versus intravenous streptokinase in acute myocardial infarction. Report from the European Cooperative Study Group for Recombinant Tissue- type Plasminogen Activator. Lancet. 1985; 1: 842-7.
  39. ↑ Boffey PM U.S. To Back Gene-Engineered Drug For Clotting. New York Times. 12 November 1987. http://www.nytimes.com/1987/11/13/us/us-to-back-gene-engineered-drug-for-clotting.html
  40. ↑ Genentech Press Release. Licensing of Activase Marks New Era in Treating Heart Attacks. 13 November 1987. https://www.gene.com/media/press-releases/4271/1987-11-13/licensing-of-activase-marks-new-era-in-t
  41. ↑ Marx J.L. Which clot-dissolving drug is best? Science. 1988; 242: 1505-6.
  42. ↑ Collen D. Coronary thrombolysis: streptokinase or recombinant tissue-type plasminogen activator? Ann Intern Med. 1990; 112: 529-38.
  43. ↑ Sobel BE, Collen D. After ISIS-3. Lancet. 1992; 339: 1225-6.
  44. ↑ Sobel BE, Collen D. Questions unresolved by the Third International Study of Infarct Survival. Am J Cardiol. 1992; 70: 385-9.
  45. ↑ An international randomized trial comparing four thrombolytic strategies for acute myocardial infarction. The GUSTO investigators. N Engl J Med. 1993; 329: 673-82.
  46. ↑ The effects of tissue plasminogen activator, streptokinase, or both on coronary-artery patency, ventricular function, and survival after acute myocardial infarction. The GUSTO Angiographic Investigators. N Engl J Med. 1993; 329: 1615-22.
  47. ↑ Sobel BE and Collen D. Controversy and clarification: preliminary results of the GUSTO trial. In: “Coronary thrombolysis in perspective”, Eds. BE Sobel and D Collen, Marcel Dekker Inc, New York, N.Y. 1993, p. 303-316.
  48. ↑ Keeley EC, Boura JA, Grines CL. Primary angioplasty versus intravenous thrombolytic therapy for acute myocardial infarction: a quantitative review of 23 randomised trials. Lancet. 2003; 361: 13-20. Review.
  49. ↑ Van de Werf FJ, Topol EJ, Sobel BE. The impact of fibrinolytic therapy for ST-segment-elevation acute myocardial infarction. J Thromb Haemost 2009; 7: 14_20.
  50. ↑ t-PA
  51. ↑ thrombolysis
  52. ↑ Tissue plasminogen activator for acute ischemic stroke. The National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group. N Engl J Med 1995; 333: 1581–7.
  53. ↑ Albers GW, Amarenco P, Easton JD, Sacco RL, Teal P; American College of Chest Physicians. Antithrombotic and thrombolytic therapy for ischemic stroke: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8thEdition). Chest. 2008; 133: 630S-69S.
  54. ↑ Wan S, Quinlan DJ, Agnelli G, Eikelboom JW. Thrombolysis compared with heparin for the initial treatment of pulmonary embolism: a meta-analysis of the randomized controlled trials. Circulation. 2004; 110: 744-9.
  55. ↑ Dong B, Jirong Y, Liu G, Wang Q, Wu T. Thrombolytic therapy for pulmonary embolism. Cochrane Database Syst Rev. 2006; 2: CD004437. Review.
  56. ↑ Watson LI, Armon MP. Thrombolysis for acute deep vein thrombosis. Cochrane Database Syst Rev. 18; 4: CD002783. Review.
  57. ↑ Bruen KJ, Ballard JR, Morris SE, Cochran A, Edelman LS, Saffle JR. Reduction of the incidence of amputation in frostbite injury with thrombolytic therapy. Arch Surg. 2007; 142: 546-51.
  58. ↑ Lijnen HR, Van Hoef B, De Cock F, Okada K, Ueshima S, Matsuo O, Collen D. On the mechanism of fibrin-specific plasminogen activation by staphylokinase. J Biol Chem. 1991; 266: 11826-32.
  59. ↑ Collen D, Van de Werf F. Coronary thrombolysis with recombinant staphylokinase in patients with evolving myocardial infarction. Circulation. 1993; 87: 1850-3.
  60. ↑ Vanderschueren S, et al. A randomized trial of recombinant staphylokinase versus alteplase for coronary artery patency in acute myocardial infarction. The STAR Trial Group. Circulation. 1995; 92: 2044-9.
  61. ↑ Press release ThromboGenics, 6 December 2006: ThromboGenics sign a licence agreement with Bharat Biotech for a new blood clot dissolvent.
  62. ↑ Press release ThromboGenics, 4 September 2007: ThromboGenics announce the successful conclusion of the technology transfer to Bharat Biotech for the production of a new blood clot dissolvent.
  63. ↑ Press release ThromboGenics, 4 October 2007: ThromboGenics and Rhein Minapharm announce an agreement on next generation thrombolytic medicines.
  64. ↑ Carmeliet P, et al. Abnormal blood vessel development and lethality in embryos lacking a single VEGF allele. Nature. 1996; 380: 435-9.
  65. ↑ Carmeliet P, et al., Targeted deficiency or cytosolic truncation of the VE-cadherin gene in mice impairs VEGFmediated endothelial survival and angiogenesis. Cell. 1999; 98: 147-57.
  66. ↑ Carmeliet P, et al. Synergism between vascular endothelial growth factor and placental growth factor contributes to angiogenesis and plasma extravasation in pathological conditions. Nat Med. 2001; 7: 575-83.
  67. ↑ Fischer C, Jonckx B, Mazzone M, Zacchigna S, Loges S, Pattarini L, Chorianopoulos E, Liesenborghs L, Koch M, De Mol M, Autiero M, Wyns S, Plaisance S, Moons L, van Rooijen N, Giacca M, Stassen JM, Dewerchin M, Collen D, Carmeliet P. Anti-PlGF inhibits growth of VEGF(R)-inhibitor-resistant tumors without affecting healthy vessels. Cell. 2007 Nov 2;131(3):463-75.
  68. ↑ Oosthuyse B, et al. Deletion of the hypoxia-response element in the vascular endothelial growth factor promoter causes motor neuron degeneration. Nat Genet. 2001; 28: 131-8.
  69. 1 2 Lambrechts D, et al. VEGF is a modifier of amyotrophic lateral sclerosis in mice and humans and protects motoneurons against ischemic death. Nat Genet. 2003; 34: 383-94.
  70. ↑ http://www.lsrp.be/index.html
  71. ↑ Stalmans P, Benz MS, Gandorfer A, Kampik A, Girach A, Pakola S, Haller JA; MIVI-TRUST Study Group. Enzymatic vitreolysis with ocriplasmin for vitreomacular traction and macular holes. N Engl J Med. 2012 Aug 16;367(7):606-15. doi:10.1056/NEJMoa1110823. PMID 22894573.
  72. ↑ Varma R, Haller JA, Kaiser PK. Improvement in Patient-Reported Visual Function After Ocriplasmin for Vitreomacular Adhesion: Results of the Microplasmin for Intravitreous Injection-Traction Release Without Surgical Treatment (MIVI-TRUST) Trials. JAMA Ophthalmol. 2015 Sep;133(9):997-1004. doi:10.1001/jamaophthalmol.2015.1746. PMID 26068086.
  73. ↑ https://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/125422_jetrea_toc.cfm
  74. ↑ http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/002381/human_med_001629.jsp&mid=WC0b01ac058001d124

This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.